Genmab (Otc) ((GMAB)), Biontech Se Sponsored Adr ((BNTX)), Biontech SE (($CC:BNTX.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Genmab and BioNTech SE are conducting a clinical study titled ‘A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors.’ The study aims to evaluate the safety and anti-tumor activity of the antibody GEN1042, alone and in combination with pembrolizumab, in patients with malignant solid tumors. This trial is significant as it explores potential new cancer treatments.
The intervention involves GEN1042, a biological treatment administered intravenously, tested alone and in combination with pembrolizumab and various chemotherapy drugs. The purpose is to assess its effectiveness in treating certain cancers.
The study is designed as an open-label, non-randomized, sequential intervention model focusing on treatment. There is no masking involved, and all participants receive active treatment.
Key dates include the actual start date of September 17, 2019, with the last update submitted on August 4, 2025. These dates are crucial for tracking the study’s progress and anticipated completion.
The market implications of this study could be significant for Genmab and BioNTech SE, potentially boosting investor confidence and stock performance if the results are favorable. The study’s outcome may also influence the competitive landscape in the oncology sector.
The study is ongoing, and further details are available on the ClinicalTrials portal.